Literature DB >> 21106221

Immunohistochemical evaluation of podocalyxin expression in glomerulopathies associated with nephrotic syndrome.

Evangelia Kavoura1, Hariklia Gakiopoulou, Helen Paraskevakou, Smaragdi Marinaki, George Agrogiannis, Anastasios Stofas, Ioannis Boletis, Efstratios Patsouris, Andreas C Lazaris.   

Abstract

It is now well established that morphological change of podocytes is closely correlated to the development of proteinuria. The aim of this study was to investigate the role of podocalyxin, a major podocyte protein, in the pathogenesis of glomerulopathies primarily associated with the nephrotic syndrome. Immunohistochemical expression of podocalyxin has been evaluated in 51 renal samples, including healthy controls, patients with podocytopathies (minimal change disease [MCD], focal segmental glomerulosclerosis [FSGS]) and membranous glomerulopathy (MG). A computerized image analysis program has been used. Statistical analysis was performed using analysis of variance and Bonferroni tests. Immunohistochemical expression of podocalyxin has been observed within the podocytes of healthy controls. In MCD, podocalyxin expression was globally reduced despite the normal appearance of the glomeruli. In FSGS, podocalyxin loss was observed in both the segmental sclerotic and the nonsclerotic areas being significantly more prominent in the former. Reduction of podocalyxin in MG was demonstrated for the first time immunohistochemically. The percentage of the stained area was statistical significantly higher in the controls than in each pathologic group. However, among pathologic groups (FSGS, MCD, MG), there was no statistically significant difference. This is one of the few studies investigating podocalyxin immunohistochemical expression in glomerulopathies associated with nephrotic syndrome. The observed reduction in podocalyxin expression suggests that it constitutes a target molecule in nephrotic syndrome pathogenesis regardless of the underlying cause. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106221     DOI: 10.1016/j.humpath.2010.05.028

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  15 in total

1.  Phosphorylation of podocalyxin (Ser415) Prevents RhoA and ezrin activation and disrupts its interaction with the actin cytoskeleton.

Authors:  Hirotaka Fukasawa; Hiroaki Obayashi; Sandra Schmieder; Jaesung Lee; Pradipta Ghosh; Marilyn G Farquhar
Journal:  Am J Pathol       Date:  2011-09-25       Impact factor: 4.307

Review 2.  Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms.

Authors:  Gabriel Cara-Fuentes; William L Clapp; Richard J Johnson; Eduardo H Garin
Journal:  Pediatr Nephrol       Date:  2016-07-06       Impact factor: 3.714

3.  Correlation between endocapillary proliferative and nephrotic-range proteinuria in children with Henoch-Schönlein purpura nephritis.

Authors:  Xiao-Qing Yang; Yan-Jie Huang; Wen-Sheng Zhai; Xian-Qing Ren; Qing-Yin Guo; Xia Zhang; Meng Yang; Jian Zhang; Ying Ding; Shan Zhu; Tatsuo Yamamoto; Yuan Sun
Journal:  Pediatr Nephrol       Date:  2018-11-10       Impact factor: 3.714

Review 4.  Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics.

Authors:  Guo-Xiang Hao; Lin-Lin Song; Dong-Feng Zhang; Le-Qun Su; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2020-01-14       Impact factor: 4.335

Review 5.  Membrane trafficking in podocyte health and disease.

Authors:  Agnieszka Swiatecka-Urban
Journal:  Pediatr Nephrol       Date:  2012-08-30       Impact factor: 3.714

6.  Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer.

Authors:  Anna Larsson; Marie Fridberg; Alexander Gaber; Björn Nodin; Per Levéen; Göran Jönsson; Mathias Uhlén; Helgi Birgisson; Karin Jirström
Journal:  BMC Cancer       Date:  2012-07-08       Impact factor: 4.430

7.  Metformin Ameliorates Podocyte Damage by Restoring Renal Tissue Podocalyxin Expression in Type 2 Diabetic Rats.

Authors:  Limin Zhai; Junfei Gu; Di Yang; Wei Wang; Shandong Ye
Journal:  J Diabetes Res       Date:  2015-05-13       Impact factor: 4.011

8.  Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.

Authors:  Kapo Saukkonen; Jaana Hagström; Harri Mustonen; Anne Juuti; Stig Nordling; Christian Fermér; Olle Nilsson; Hanna Seppänen; Caj Haglund
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

9.  Regulation of podocalyxin expression in the kidney of streptozotocin-induced diabetic rats with Chinese herbs (Yishen capsule).

Authors:  Jingai Fang; Hongkun Wei; Yanyan Sun; Xiaodong Zhang; Wenyuan Liu; Qintao Chang; Ruihua Wang; Yuewen Gong
Journal:  BMC Complement Altern Med       Date:  2013-04-05       Impact factor: 3.659

10.  An overview of molecular mechanism of nephrotic syndrome.

Authors:  Juliana Reis Machado; Laura Penna Rocha; Precil Diego Miranda de Menezes Neves; Eliângela de Castro Cobô; Marcos Vinícius Silva; Lúcio Roberto Castellano; Rosana Rosa Miranda Corrêa; Marlene Antônia Reis
Journal:  Int J Nephrol       Date:  2012-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.